Susquehanna International Group’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Susquehanna International Group’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,272	Closed	-$79K	–	14635
2021 Q4	$79K	Sell	5,272 -4,128	-44%	-$97.7K	﹤0.01%	12296
2021 Q3	$280K	Sell	9,400 -13,292	-59%	-$375K	﹤0.01%	10757
2021 Q2	$766K	Buy	22,692 +496	+2%	+$18.5K	﹤0.01%	8497
2021 Q1	$921K	Buy	22,196 +17,396	+362%	+$1.08M	﹤0.01%	7958
2020 Q4	$290K	Buy	4,800 +4,145	+633%	+$449K	﹤0.01%	9338
2020 Q3	$87K	Buy	655 +387	+144%	+$64.7K	﹤0.01%	9995
2020 Q2	$45K	Buy	268 +184	+219%	+$30.7K	﹤0.01%	9781
2020 Q1	$12K	Buy	84 +31	+58%	+$9.48K	﹤0.01%	10027
2019 Q4	$18K	Sell	53 -5	-9%	-$2.29K	﹤0.01%	9502
2019 Q3	$29K	Buy	+58	New	+$32.7K	﹤0.01%	9903
2019 Q2	–	Sell	-354	Closed	-$216K	–	11129
2019 Q1	$216K	Buy	+354	New	+$193K	﹤0.01%	7770
2018 Q3	–	Sell	-173	Closed	-$150K	–	10646
2018 Q2	$150K	Buy	173 +125	+260%	+$143K	﹤0.01%	8838
2018 Q1	$61K	Buy	+48	New	+$71K	﹤0.01%	8896

Other funds holding NBRV

VFA

Values First Advisors Gray, Tennessee $219M AUM 33.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Susquehanna International Group's NBRV Position: Q1 2023 in Review

Susquehanna International Group sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q1 2023, closing a stake of 22,294 shares — an estimated $41K sold.

Susquehanna International Group first reported a position in NBRV in Q4 2017 and held it in 17 quarters. The position peaked at $1.11M in Q2 2019. 12 funds tracked by Wall St. Rank hold NBRV as of Q1 2023.

Susquehanna International Group reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q1 2023 after selling out during the quarter.
Susquehanna International Group sold 22,294 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q1 2023, an estimated $41K.
Susquehanna International Group first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2017 and held it in 17 quarters.
Susquehanna International Group's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $1.11M in Q2 2019.
12 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q1 2023.

Based on Susquehanna International Group's 13F filing for Q1 2023, filed 16 May 2023.